Genenta Science S.p.A.
GNTA
NASDAQ·Healthcare·Biotechnology·Mkt cap $18.4M
$0.96
▲ +1.01%
P/E
—
Mkt Cap
$18.4M
52-Wk Range
$0.55–$10.00
52-Week Range
$0.55 - $10.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 72.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-52.9% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GNTA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
Earnings recap unavailable for this period.
Reported EPS · last 4Q
No quarterly earnings data on file.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GNTA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.